Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Hiroshi Teranaka"'
Autor:
Hiroyoshi Kunimoto, Takayuki Sakuma, Takuma Ohashi, Mayoko Shirafuta, Hiroshi Teranaka, Hideaki Nakajima
Publikováno v:
eJHaem, Vol 5, Iss 6, Pp 1335-1339 (2024)
Abstract Anemia is a major clinical manifestation seen in myelodysplastic syndromes (MDS). Treatment options for anemia in low‐risk MDS are limited. Especially, oral medication which is uniformly effective for anemia in low‐risk MDS is required.
Externí odkaz:
https://doaj.org/article/8eb2c1477706421092e1f04684dc4fa3
Autor:
Hiroyoshi Kunimoto, Yumi Fukuchi, Koichi Murakami, Junji Ikeda, Hiroshi Teranaka, Ikuma Kato, Takuya Miyazaki, Makiko Enaka, Takayuki Mitsuhashi, Etsuko Yamazaki, Kaori Kameyama, Mitsuru Murata, Shinichiro Okamoto, Hideaki Nakajima
Publikováno v:
HemaSphere, Vol 4, Iss 5, p e469 (2020)
Abstract. Acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) with both inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and monosomy 7 defines an extremely aggressive myeloid cancer whose molecular pathogenesis and optimal therapeutic strategy still r
Externí odkaz:
https://doaj.org/article/92b2e246fb4b4dbd905e872de929759c
Autor:
Takuma Ohashi, Kaoru Takase-Minegishi, Ayaka Maeda, Naoki Hamada, Ryusuke Yoshimi, Yohei Kirino, Hiroshi Teranaka, Hiroyoshi Kunimoto, Maki Hagihara, Kenji Matsumoto, Ho Namkoong, Nobuyuki Horita, Hideaki Nakajima
Publikováno v:
Journal of Hematology. 12:66-74
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a042d2f7bc09400dd39a227239950ec
https://doi.org/10.14740/jh1090
https://doi.org/10.14740/jh1090
Autor:
Masahiro Akimoto, Takuya Miyazaki, Hiroyuki Takahashi, Yusuke Saigusa, Takaaki Takeda, Yuto Hibino, Mayumi Tokunaga, Takuma Ohashi, Ayako Matsumura, Haruka Teshigawara, Taisei Suzuki, Hiroshi Teranaka, Yuki Nakajima, Kenji Matsumoto, Chizuko Hashimoto, Katsumichi Fujimaki, Hiroyuki Fujita, Rika Sakai, Shin Fujisawa, Hideaki Nakajima
Publikováno v:
Blood. 140:3809-3810
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd3a748877fc1d404838289988441b8c
https://doi.org/10.1182/blood-2022-157951
https://doi.org/10.1182/blood-2022-157951
Autor:
Taiki Ando, Hideaki Nakajima, Maki Hagihara, Eriko Ogusa, Hiroshi Teranaka, Ayako Matsumura, Taisei Suzuki, Takuya Miyazaki, Yuki Nakajima, Shin Fujisawa, Takayuki Sakuma, Yoshimi Ishii, Hiroyuki Takahashi, Kazuho Miyashita, Haruka Teshigawara, Kenji Matsumoto, Etsuko Yamazaki
Publikováno v:
International Journal of Hematology. 112:46-56
We analyzed clinical cutoffs for defining computed tomography (CT) methods for sarcopenia and examined the prognostic value of CT for allogeneic hematopoietic stem cell transplantation (allo-HCST) outcomes of patients with myeloid malignancy. One hun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbacf123e8f61ddc04c4d84aa4878843
https://doi.org/10.1007/s12185-020-02870-5
https://doi.org/10.1007/s12185-020-02870-5
Autor:
Etsuko Yamazaki, Ikuma Kato, Hiroshi Teranaka, Shinichiro Okamoto, Makiko Enaka, Takayuki Mitsuhashi, Koichi Murakami, Kaori Kameyama, Hideaki Nakajima, Mitsuru Murata, Yumi Fukuchi, Junji Ikeda, Takuya Miyazaki, Hiroyoshi Kunimoto
Publikováno v:
HemaSphere, Vol 4, Iss 5, p e469 (2020)
HemaSphere
HemaSphere
Acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) with both inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and monosomy 7 defines an extremely aggressive myeloid cancer whose molecular pathogenesis and optimal therapeutic strategy still remain uncl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f218ccbbf1086063da3f7032557b4c7d
https://doi.org/10.1097/hs9.0000000000000469
https://doi.org/10.1097/hs9.0000000000000469